Hepatic OATP1B transporters and nuclear receptors PXR and CAR: Interplay, regulation of drug disposition genes, and single nucleotide polymorphisms

Molecular Pharmaceutics

Volumn 6, Issue 6, 2009, Pages 1644-1661

  Meyer Zu Schwabedissen, Henriette E ^a,b   Kim, Richard B ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Constitutive androstane receptor; Farnesoid X receptor; Nuclear receptor; Organic anion transporting polypeptide; Pregnane X receptor; Single nucleotide polymorphism; Transactivation; Vitamin D receptor

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 4,4' ISOPROPYLIDENEDIPHENOL; ALDRIN; ARTEMISININ; ATORVASTATIN; CARBAMAZEPINE; CERIVASTATIN; CHLORDANE; CHLORDECONE; CHLORPHENOTANE; CHLORPYRIFOS; CIPERMETHRIN; CISPLATIN; CLINDAMYCIN; CLOTRIMAZOLE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DICLOXACILLIN; DIELDRIN; DOCETAXEL; DRUG METABOLIZING ENZYME; ECONAZOLE; EFAVIRENZ; ENDOSULFAN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; PREGNANE X RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONCEPTUAL FRAMEWORK; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; HUMANS; LIVER; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID;

EID: 71949119028     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp9000298     Document Type: Review

References (203)

1. Eichelbaum, M.; Ingelman-Sundberg, M.; Evans, W. E. Pharmacogenomics and Individualized Drug Therapy. Annu. Rev. Med. 2006, 57, 119-137.
2. Bertz, R. J.; Granneman, G. R. Use of in Vitro and in Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions. Clin. Pharmacokinet. 1997, 32, 210-258.
3. Ozdemir, V.; Kalow, W.; Tang, B. K.; Paterson, A. D.; Walker, S. E.; Endrenyi, L.; Kashuba, A. D. Evaluation of the Genetic Component of Variability in CYP3A4 Activity: a Repeated Drug Administration Method. Pharmacogenetics 2000, 10, 373-388.
4. Thummel, K. E.; Wilkinson, G. R. In Vitro and in Vivo Drug Interactions Involving Human CYP3A. Annu. Rev. Pharmacol. Toxicol. 1998, 38, 389-430. (Pubitemid 28231501)
5. Wilkinson, G. R. Drug Metabolism and Variability Among Patients in Drug Response. N. Engl. J. Med. 2005, 352, 2211-2221.
6. Chawla, A.; Repa, J. J.; Evans, R. M.; Mangelsdorf, D. J. Nuclear Receptors and Lipid Physiology: Opening the X-Files. Science 2001, 294, 1866-1870.
7. Bain, D. L.; Heneghan, A. F.; Connaghan-Jones, K. D.; Miura, M. T. Nuclear Receptor Structure: Implications for Function. Annu. Rev. Physiol. 2007, 69, 201-220. (Pubitemid 46457641)
8. Urquhart, B. L.; Tirona, R. G.; Kim, R. B. Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs. J. Clin. Pharmacol. 2007, 47, 566-578.
9. Lehmann, J. M.; McKee, D. D.; Watson, M. A.; Willson, T. M.; Moore, J. T.; Kliewer, S. A. The Human Orphan Nuclear Receptor PXR Is Activated by Compounds That Regulate CYP3A4 Gene Expression and Cause Drug Interactions. J. Clin. Invest. 1998, 102, 1016-1023.
10. Staudinger, J. L.; Goodwin, B.; Jones, S. A.; Hawkins-Brown, D.; MacKenzie, K. I.; LaTour, A.; Liu, Y.; Klaassen, C. D.; Brown, K. K.; Reinhard, J.; Willson, T. M.; Koller, B. H.; Kliewer, S. A. The Nuclear Receptor PXR Is a Lithocholic Acid Sensor That Protects Against Liver Toxicity. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3369-3374.
11. Xie, W.; Barwick, J. L.; Downes, M.; Blumberg, B.; Simon, C. M.; Nelson, M. C.; Neuschwander-Tetri, B. A.; Brunt, E. M.; Guzelian, P. S.; Evans, R. M. Humanized Xenobiotic Response in Mice Expressing Nuclear Receptor SXR. Nature 2000, 406, 435-439.
12. Ma, X.; Cheung, C.; Krausz, K. W.; Shah, Y. M.; Wang, T.; Idle, J. R.; Gonzalez, F. J. A Double Transgenic Mouse Model Expressing Human Pregnane X Receptor and Cytochrome P450 3A4. Drug Metab. Dispos. 2008, 36, 2506-2512.
13. Scheer, N.; Ross, J.; Rode, A.; Zevnik, B.; Niehaves, S.; Faust, N.; Wolf, C. R. A Novel Panel of Mouse Models to Evaluate the Role of Human Pregnane X Receptor and Constitutive Androstane Receptor in Drug Response. J. Clin. Invest. 2008, 118, 3228-3239.
14. Ma, X.; Idle, J. R.; Gonzalez, F. J. The Pregnane X Receptor: From Bench to Bedside. Expert. Opin. Drug Metab. Toxicol. 2008, 4, 895-908.
15. Tirona, R. G.; Leake, B. F.; Podust, L. M.; Kim, R. B. Identification of Amino Acids in Rat Pregnane X Receptor That Determine Species-Specific Activation. Mol. Pharmacol. 2004, 65, 36-44.
16. Zhang, J.; Kuehl, P.; Green, E. D.; Touchman, J. W.; Watkins, P. B.; Daly, A.; Hall, S. D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Wrighton, S. A.; Hancock, M.; Kim, R. B.; Strom, S.; Thummel, K.; Russell, C. G.; Hudson, J. R., Jr.; Schuetz, E. G.; Boguski, M. S. The Human Pregnane X Receptor: Genomic Structure and Identification and Functional Characterization of Natural Allelic Variants. Pharmacogenetics 2001, 11, 555-572.
17. Hustert, E.; Zibat, A.; Presecan-Siedel, E.; Eiselt, R.; Mueller, R.; Fuss, C.; Brehm, I.; Brinkmann, U.; Eichelbaum, M.; Wojnowski, L.; Burk, O. Natural Protein Variants of Pregnane X Receptor With Altered Transactivation Activity Toward CYP3A4. Drug Metab. Dispos. 2001, 29, 1454-1459. (Pubitemid 33000692)
18. King, C. R.; Xiao, M.; Yu, J.; Minton, M. R.; Addleman, N. J.; Van Booven, D. J.; Kwok, P. Y.; McLeod, H. L.; Marsh, S. Identification of NR1I2 Genetic Variation Using Resequencing. Eur. J. Clin. Pharmacol. 2007, 63, 547-554. (Pubitemid 46684492)
19. Bosch, T. M.; Deenen, M.; Pruntel, R.; Smits, P. H.; Schellens, J. H.; Beijnen, J. H.; Meijerman, I. Screening for Polymorphisms in the PXR Gene in a Dutch Population. Eur. J. Clin. Pharmacol. 2006, 62, 395-399.
20. Koyano, S.; Kurose, K.; Ozawa, S.; Saeki, M.; Nakajima, Y.; Hasegawa, R.; Komamura, K.; Ueno, K.; Kamakura, S.; Nakajima, T.; Saito, H.; Kimura, H.; Goto, Y.; Saitoh, O.; Katoh, M.; Ohnuma, T.; Kawai, M.; Sugai, K.; Ohtsuki, T.; Suzuki, C.; Minami, N.; Saito, Y.; Sawada, J. Eleven Novel Single Nucleotide Polymorphisms in the NR1I2 (PXR) Gene, Four of Which Induce Non-Synonymous Amino Acid Alterations. Drug Metab. Pharmacokinet. 2002, 17, 561-565.
21. Koyano, S.; Kurose, K.; Saito, Y.; Ozawa, S.; Hasegawa, R.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Nakajima, T.; Matsumoto, K.; Akasawa, A.; Saito, H.; Sawada, J. Functional Characterization of Four Naturally Occurring Variants of Human Pregnane X Receptor (PXR): One Variant Causes Dramatic Loss of Both DNA Binding Activity and the Transactivation of the CYP3A4 Promoter/Enhancer Region. Drug Metab. Dispos. 2004, 32, 149-154. (Pubitemid 38112547)
22. Lim, Y. P.; Liu, C. H.; Shyu, L. J.; Huang, J. D. Functional Characterization of a Novel Polymorphism of Pregnane X Receptor, Q158K, in Chinese Subjects. Pharmacogenet. Genomics 2005, 15, 337-341.
23. Owen, B. M.; Van Mil, S. W.; Boudjelal, M.; McLay, I.; Cairns, W.; Elias, E.; White, R.; Williamson, C.; Dixon, P. H. Sequencing and Functional Assessment of HPXR (NR1I2) Variants in Intrahepatic Cholestasis of Pregnancy. Xenobiotica 2008, 38, 1289-1297.
24. Lamba, J.; Lamba, V.; Strom, S.; Venkataramanan, R.; Schuetz, E. Novel Single Nucleotide Polymorphisms in the Promoter and Intron 1 of Human Pregnane X Receptor/NR1I2 and Their Association With CYP3A4 Expression. Drug Metab. Dispos. 2008, 36, 169-181.
25. Sandanaraj, E.; Lal, S.; Selvarajan, V.; Ooi, L. L.; Wong, Z. W.; Wong, N. S.; Ang, P. C.; Lee, E. J.; Chowbay, B. PXR Pharmacogenetics: Association of Haplotypes With Hepatic CYP3A4 and ABCB1 Messenger RNA Expression and Doxorubicin Clearance in Asian Breast Cancer Patients. Clin. Cancer Res. 2008, 14, 7116-7126.
26. Hor, S. Y.; Lee, S. C.; Wong, C. I.; Lim, Y. W.; Lim, R. C.; Wang, L. Z.; Fan, L.; Guo, J. Y.; Lee, H. S.; Goh, B. C.; Tan, T. PXR, CAR and HNF4alpha Genotypes and Their Association With Pharmacokinetics and Pharmacodynamics of Docetaxel and Doxorubicin in Asian Patients. Pharmacogenomics J. 2008, 8, 139-146.
27. Tham, L. S.; Holford, N. H.; Hor, S. Y.; Tan, T.; Wang, L.; Lim, R. C.; Lee, H. S.; Lee, S. C.; Goh, B. C. Lack of Association of Single-Nucleotide Polymorphisms in Pregnane X Receptor, Hepatic Nuclear Factor 4alpha, and Constitutive Androstane Receptor With Docetaxel Pharmacokinetics. Clin. Cancer Res. 2007, 13, 7126-7132.
28. Dring, M. M.; Goulding, C. A.; Trimble, V. I.; Keegan, D.; Ryan, A. W.; Brophy, K. M.; Smyth, C. M.; Keeling, P. W.; O'Donoghue, D.; O'Sullivan, M.; O'Morain, C.; Mahmud, N.; Wikstrom, A. C.; Kelleher, D.; McManus, R. The Pregnane X Receptor Locus Is Associated With Susceptibility to Inflammatory Bowel Disease. Gastroenterology 2006, 130, 341-348. (Pubitemid 43202034)
29. Martinez, A.; Marquez, A.; Mendoza, J.; Taxonera, C.; Fernandez-Arquero, M.; Diaz-Rubio, M.; de la Concha, E. G.; Urcelay, E. Role of the PXR Gene Locus in Inflammatory Bowel Diseases. Inflammatory Bowel Dis. 2007, 13, 1484-1487.
30. Sueyoshi, T.; Kawamoto, T.; Zelko, I.; Honkakoski, P.; Negishi, M. The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene. J. Biol. Chem. 1999, 274, 6043-6046. (Pubitemid 29111006)
31. Honkakoski, P.; Zelko, I.; Sueyoshi, T.; Negishi, M. The Nuclear Orphan Receptor CAR-Retinoid X Receptor Heterodimer Activates the Phenobarbital- Responsive Enhancer Module of the CYP2B Gene. Mol. Cell. Biol. 1998, 18, 5652-5658. (Pubitemid 28450516)
32. Ferguson, S. S.; Chen, Y.; LeCluyse, E. L.; Negishi, M.; Goldstein, J. A. Human CYP2C8 Is Transcriptionally Regulated by the Nuclear Receptors Constitutive Androstane Receptor, Pregnane X Receptor, Glucocorticoid Receptor, and Hepatic Nuclear Factor 4alpha. Mol. Pharmacol. 2005, 68, 747-757. (Pubitemid 41206028)
33. Gerbal-Chaloin, S.; Daujat, M.; Pascussi, J. M.; Pichard-Garcia, L.; Vilarem, M. J.; Maurel, P. Transcriptional Regulation of CYP2C9 Gene. Role of Glucocorticoid Receptor and Constitutive Androstane Receptor. J. Biol. Chem. 2002, 277, 209-217. (Pubitemid 34952047)
34. Goodwin, B.; Hodgson, E.; D'Costa, D. J.; Robertson, G. R.; Liddle, C. Transcriptional Regulation of the Human CYP3A4 Gene by the Constitutive Androstane Receptor. Mol. Pharmacol. 2002, 62, 359-365. (Pubitemid 34804117)
35. Bertilsson, G.; Berkenstam, A.; Blomquist, P. Functionally Conserved Xenobiotic Responsive Enhancer in Cytochrome P450 3A7. Biochem. Biophys. Res. Commun. 2001, 280, 139-144. (Pubitemid 32917487)
36. Burk, O.; Arnold, K. A.; Geick, A.; Tegude, H.; Eichelbaum, M. A Role for Constitutive Androstane Receptor in the Regulation of Human Intestinal MDR1 Expression. Biol. Chem. 2005, 386, 503-513. (Pubitemid 41447572)
37. Kast, H. R.; Goodwin, B.; Tarr, P. T.; Jones, S. A.; Anisfeld, A. M.; Stoltz, C. M.; Tontonoz, P.; Kliewer, S.; Willson, T. M.; Edwards, P. A. Regulation of Multidrug Resistance-Associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-Activated Receptor, and Constitutive Androstane Receptor. J. Biol. Chem. 2002, 277, 2908-2915.
38. Sugatani, J.; Yamakawa, K.; Tonda, E.; Nishitani, S.; Yoshinari, K.; Degawa, M.; Abe, I.; Noguchi, H.; Miwa, M. The Induction of Human UDP-Glucuronosyltransferase 1A1 Mediated Through a Distal Enhancer Module by Flavonoids and Xenobiotics. Biochem. Pharmacol. 2004, 67, 989-1000. (Pubitemid 38201644)
39. Blumberg, B.; Sabbagh, W., Jr.; Juguilon, H.; Bolado, J., Jr.; van Meter, C. M.; Ong, E. S.; Evans, R. M. SXR, a Novel Steroid and Xenobiotic-Sensing Nuclear Receptor. Genes Dev. 1998, 12, 3195-3205.
40. Waxman, D. J. P450 Gene Induction by Structurally Diverse Xenochemicals: Central Role of Nuclear Receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 1999, 369, 11-23.
41. Suino, K.; Peng, L.; Reynolds, R.; Li, Y.; Cha, J. Y.; Repa, J. J.; Kliewer, S. A.; Xu, H. E. The Nuclear Xenobiotic Receptor CAR: Structural Determinants of Constitutive Activation and Heterodimerization. Mol. Cell 2004, 16, 893-905.
42. Pascussi, J. M.; Drocourt, L.; Gerbal-Chaloin, S.; Fabre, J. M.; Maurel, P.; Vilarem, M. J. Dual Effect of Dexamethasone on CYP3A4 Gene Expression in Human Hepatocytes. Sequential Role of Glucocorticoid Receptor and Pregnane X Receptor. Eur. J. Biochem. 2001, 268, 6346-6358.
43. Rencurel, F.; Foretz, M.; Kaufmann, M. R.; Stroka, D.; Looser, R.; Leclerc, I.; da, S. X.; Rutter, G. A.; Viollet, B.; Meyer, U. A. Stimulation of AMP-Activated Protein Kinase Is Essential for the Induction of Drug Metabolizing Enzymes by Phenobarbital in Human and Mouse Liver. Mol. Pharmacol. 2006, 70, 1925-1934.
44. Koike, C.; Moore, R.; Negishi, M. Extracellular Signal-Regulated Kinase Is an Endogenous Signal Retaining the Nuclear Constitutive Active/Androstane Receptor (CAR) in the Cytoplasm of Mouse Primary Hepatocytes. Mol. Pharmacol. 2007, 71, 1217-1221. (Pubitemid 46658675)
45. Yoshinari, K.; Kobayashi, K.; Moore, R.; Kawamoto, T.; Negishi, M. Identification of the Nuclear Receptor CAR:HSP90 Complex in Mouse Liver and Recruitment of Protein Phosphatase 2A in Response to Phenobarbital. FEBS Lett. 2003, 548, 17-20. (Pubitemid 37281243)
46. Sueyoshi, T.; Moore, R.; Sugatani, J.; Matsumura, Y.; Negishi, M. PPP1R16A, the Membrane Subunit of Protein Phosphatase 1beta, Signals Nuclear Translocation of the Nuclear Receptor Constitutive Active/Androstane Receptor. Mol. Pharmacol. 2008, 73, 1113-1121.
47. Hosseinpour, F.; Timsit, Y.; Koike, C.; Matsui, K.; Yamamoto, Y.; Moore, R.; Negishi, M. Overexpression of the Rho-Guanine Nucleotide Exchange Factor ECT2 Inhibits Nuclear Translocation of Nuclear Receptor CAR in the Mouse Liver. FEBS Lett. 2007, 581, 4937-4942. (Pubitemid 47531764)
48. Tzameli, I.; Pissios, P.; Schuetz, E. G.; Moore, D. D. The Xenobiotic Compound 1,4-Bis[2-(3,5-Dichloropyridyloxy)]Benzene Is an Agonist Ligand for the Nuclear Receptor CAR. Mol. Cell. Biol. 2000, 20, 2951-2958.
49. Forman, B. M.; Tzameli, I.; Choi, H. S.; Chen, J.; Simha, D.; Seol, W.; Evans, R. M.; Moore, D. D. Androstane Metabolites Bind to and Deactivate the Nuclear Receptor CAR-Beta. Nature 1998, 395, 612-615.
50. Moore, L. B.; Parks, D. J.; Jones, S. A.; Bledsoe, R. K.; Consler, T. G.; Stimmel, J. B.; Goodwin, B.; Liddle, C.; Blanchard, S. G.; Willson, T. M.; Collins, J. L.; Kliewer, S. A. Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands. J. Biol. Chem. 2000, 275, 15122-15127.
51. Li, L.; Chen, T.; Stanton, J. D.; Sueyoshi, T.; Negishi, M.; Wang, H. The Peripheral Benzodiazepine Receptor Ligand 1-(2-Chlorophenyl-Methylpropyl)-3- Isoquinoline-Carboxamide Is a Novel Antagonist of Human Constitutive Androstane Receptor. Mol. Pharmacol. 2008, 74, 443-453.
52. Guo, G. L.; Lambert, G.; Negishi, M.; Ward, J. M.; Brewer, H. B., Jr.; Kliewer, S. A.; Gonzalez, F. J.; Sinal, C. J. Complementary Roles of Farnesoid X Receptor, Pregnane X Receptor, and Constitutive Androstane Receptor in Protection Against Bile Acid Toxicity. J. Biol. Chem. 2003, 278, 45062-45071.
53. Saini, S. P.; Sonoda, J.; Xu, L.; Toma, D.; Uppal, H.; Mu, Y.; Ren, S.; Moore, D. D.; Evans, R. M.; Xie, W. A Novel Constitutive Androstane Receptor-Mediated and CYP3A-Independent Pathway of Bile Acid Detoxification. Mol. Pharmacol. 2004, 65, 292-300.
54. Qatanani, M.; Zhang, J.; Moore, D. D. Role of the Constitutive Androstane Receptor in Xenobiotic-Induced Thyroid Hormone Metabolism. Endocrinology 2005, 146, 995-1002. (Pubitemid 40289286)
55. Moreau, A.; Vilarem, M. J.; Maurel, P.; Pascussi, J. M. Xenoreceptors CAR and PXR Activation and Consequences on Lipid Metabolism, Glucose Homeostasis, and Inflammatory Response. Mol. Pharmaceutics 2008, 5, 35-41.
56. Finn, R. D.; Henderson, C. J.; Scott, C. L.; Wolf, C. R. Unsaturated Fatty Acid Regulation of Cytochrome P450 Expression Via a CAR-Dependent Pathway. Biochem. J. 2009, 417, 43-54.
57. Masson, D.; Qatanani, M.; Sberna, A. L.; Xiao, R.; Pais de Barros, J. P.; Grober, J.; Deckert, V.; Athias, A.; Gambert, P.; Lagrost, L.; Moore, D. D.; Assem, M. Activation of the Constitutive Androstane Receptor Decreases HDL in Wild-Type and Human ApoA-I Transgenic Mice. J. Lipid Res. 2008, 49, 1682-1691.
58. Roth, A.; Looser, R.; Kaufmann, M.; Blattler, S. M.; Rencurel, F.; Huang, W.; Moore, D. D.; Meyer, U. A. Regulatory Cross-Talk Between Drug Metabolism and Lipid Homeostasis: Constitutive Androstane Receptor and Pregnane X Receptor Increase Insig-1 Expression. Mol. Pharmacol. 2008, 73, 1282-1289.
59. Ikeda, S.; Kurose, K.; Ozawa, S.; Sai, K.; Hasegawa, R.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Tomoike, H.; Nakajima, T.; Matsumoto, K.; Saito, H.; Goto, Y.; Kimura, H.; Katoh, M.; Sugai, K.; Minami, N.; Shirao, K.; Tamura, T.; Yamamoto, N.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Saito, Y.; Sawada, J. Twenty-Six Novel Single Nucleotide Polymorphisms and Their Frequencies of the NR1I3 (CAR) Gene in a Japanese Population. Drug Metab. Pharmacokinet. 2003, 18, 413-418.
60. Ikeda, S.; Kurose, K.; Jinno, H.; Sai, K.; Ozawa, S.; Hasegawa, R.; Komamura, K.; Kotake, T.; Morishita, H.; Kamakura, S.; Kitakaze, M.; Tomoike, H.; Tamura, T.; Yamamoto, N.; Kunitoh, H.; Yamada, Y.; Ohe, Y.; Shimada, Y.; Shirao, K.; Kubota, K.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Saito, Y.; Sawada, J. Functional Analysis of Four Naturally Occurring Variants of Human Constitutive Androstane Receptor. Mol. Genet. Metab. 2005, 86, 314-319. (Pubitemid 41412190)
61. Lamba, J. K. Pharmacogenetics of the Constitutive Androstane Receptor. Pharmacogenomics 2008, 9, 71-83.
62. Lamba, J.; Lamba, V.; Schuetz, E. Genetic Variants of PXR (NR1I2) and CAR (NR1I3) and Their Implications in Drug Metabolism and Pharmacogenetics. Curr. Drug Metab. 2005, 6, 369-383. (Pubitemid 41086769)
63. Hagenbuch, B.; Meier, P. J. Organic Anion Transporting Polypeptides of the OATP/ SLC21 Family: Phylogenetic Classification As OATP/ SLCO Superfamily, New Nomenclature and Molecular/Functional Properties. Pfluegers Arch. 2004, 447, 653-665.
64. Abe, T.; Kakyo, M.; Tokui, T.; Nakagomi, R.; Nishio, T.; Nakai, D.; Nomura, H.; Unno, M.; Suzuki, M.; Naitoh, T.; Matsuno, S.; Yawo, H. Identification of a Novel Gene Family Encoding Human Liver-Specific Organic Anion Transporter LST-1. J. Biol. Chem. 1999, 274, 17159-17163. (Pubitemid 129519049)
65. Konig, J.; Cui, Y.; Nies, A. T.; Keppler, D. A Novel Human Organic Anion Transporting Polypeptide Localized to the Basolateral Hepatocyte Membrane. Am. J. Physiol. 2000, 278, G156-G164. (Pubitemid 30108080)
66. Abe, T.; Unno, M.; Onogawa, T.; Tokui, T.; Kondo, T. N.; Nakagomi, R.; Adachi, H.; Fujiwara, K.; Okabe, M.; Suzuki, T.; Nunoki, K.; Sato, E.; Kakyo, M.; Nishio, T.; Sugita, J.; Asano, N.; Tanemoto, M.; Seki, M.; Date, F.; Ono, K.; Kondo, Y.; Shiiba, K.; Suzuki, M.; Ohtani, H.; Shimosegawa, T.; Iinuma, K.; Nagura, H.; Ito, S.; Matsuno, S. LST-2, a Human Liver-Specific Organic Anion Transporter, Determines Methotrexate Sensitivity in Gastrointestinal Cancers. Gastroenterology 2001, 120, 1689-1699.
67. Ho, R. H.; Tirona, R. G.; Leake, B. F.; Glaeser, H.; Lee, W.; Lemke, C. J.; Wang, Y.; Kim, R. B. Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics. Gastroenterology 2006, 130, 1793-1806.
68. Hsiang, B.; Zhu, Y.; Wang, Z.; Wu, Y.; Sasseville, V.; Yang, W. P.; Kirchgessner, T. G. A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2). Identification of a Liver-Specific Human Organic Anion Transporting Polypeptide and Identification of Rat and Human Hydroxymethylglutaryl-CoA Reductase Inhibitor Transporters. J. Biol. Chem. 1999, 274, 37161-37168. (Pubitemid 30016792)
69. Kameyama, Y.; Yamashita, K.; Kobayashi, K.; Hosokawa, M.; Chiba, K. Functional Characterization of SLCO1B1 (OATP-C) Variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by Using Transient Expression Systems of HeLa and HEK293 Cells. Pharmacogenet. Genomics 2005, 15, 513-522. (Pubitemid 41017600)
70. Kopplow, K.; Letschert, K.; Konig, J.; Walter, B.; Keppler, D. Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells. Mol. Pharmacol. 2005, 68, 1031-1038. (Pubitemid 41345794)
71. Noe, J.; Portmann, R.; Brun, M. E.; Funk, C. Substrate-Dependent Drug-Drug Interactions Between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 2007, 35, 1308-1314.
72. Chen, C.; Mireles, R. J.; Campbell, S. D.; Lin, J.; Mills, J. B.; Xu, J. J.; Smolarek, T. A. Differential Interaction of 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitors With ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 2005, 33, 537-546.
73. Tirona, R. G.; Leake, B. F.; Merino, G.; Kim, R. B. Polymorphisms in OATP-C: Identification of Multiple Allelic Variants Associated With Altered Transport Activity Among Europeanand African-Americans. J. Biol. Chem. 2001, 276, 35669-35675. (Pubitemid 37384369)
74. Ho, R. H.; Choi, L.; Lee, W.; Mayo, G.; Schwarz, U. I.; Tirona, R. G.; Bailey, D. G.; Michael, S. C.; Kim, R. B. Effect of Drug Transporter Genotypes on Pravastatin Disposition in European- and African-American Participants. Pharmacogenet. Genomics 2007, 17, 647-656.
75. Nishizato, Y.; Ieiri, I.; Suzuki, H.; Kimura, M.; Kawabata, K.; Hirota, T.; Takane, H.; Irie, S.; Kusuhara, H.; Urasaki, Y.; Urae, A.; Higuchi, S.; Otsubo, K.; Sugiyama, Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) Genes: Consequences for Pravastatin Pharmacokinetics. Clin. Pharmacol. Ther. 2003, 73, 554-565. (Pubitemid 37249126)
76. Niemi, M.; Schaeffeler, E.; Lang, T.; Fromm, M. F.; Neuvonen, M.; Kyrklund, C.; Backman, J. T.; Kerb, R.; Schwab, M.; Neuvonen, P. J.; Eichelbaum, M.; Kivisto, K. T. High Plasma Pravastatin Concentrations Are Associated With Single Nucleotide Polymorphisms and Haplotypes of Organic Anion Transporting Polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004, 14, 429-440.
77. Mwinyi, J.; Johne, A.; Bauer, S.; Roots, I.; Gerloff, T. Evidence for Inverse Effects of OATP-C (SLC21A6) 5 and 1b Haplotypes on Pravastatin Kinetics. Clin. Pharmacol. Ther. 2004, 75, 415-421. (Pubitemid 38534562)
78. Chung, J. Y.; Cho, J. Y.; Yu, K. S.; Kim, J. R.; Oh, D. S.; Jung, H. R.; Lim, K. S.; Moon, K. H.; Shin, S. G.; Jang, I. J. Effect of OATP1B1 (SLCO1B1) Variant Alleles on the Pharmacokinetics of Pitavastatin in Healthy Volunteers. Clin. Pharmacol. Ther. 2005, 78, 342-350.
79. Ieiri, I.; Suwannakul, S.; Maeda, K.; Uchimaru, H.; Hashimoto, K.; Kimura, M.; Fujino, H.; Hirano, M.; Kusuhara, H.; Irie, S.; Higuchi, S.; Sugiyama, Y. SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers. Clin. Pharmacol. Ther. 2007, 82, 541-547.
80. Pasanen, M. K.; Neuvonen, M.; Neuvonen, P. J.; Niemi, M. SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid. Pharmacogenet. Genomics 2006, 16, 873-879. (Pubitemid 44772805)
81. Werner, D.; Werner, U.; Meybaum, A.; Schmidt, B.; Umbreen, S.; Grosch, A.; Lestin, H. G.; Graf, B.; Zolk, O.; Fromm, M. F. Determinants of Steady-State Torasemide Pharmacokinetics: Impact of Pharmacogenetic Factors, Gender and Angiotensin II Receptor Blockers. Clin. Pharmacokinet. 2008, 47, 323-332.
82. Niemi, M.; Backman, J. T.; Kajosaari, L. I.; Leathart, J. B.; Neuvonen, M.; Daly, A. K.; Eichelbaum, M.; Kivisto, K. T.; Neuvonen, P. J. Polymorphic Organic Anion Transporting Polypeptide 1B1 Is a Major Determinant of Repaglinide Pharmacokinetics. Clin. Pharmacol. Ther. 2005, 77, 468-478.
83. Kalliokoski, A.; Neuvonen, M.; Neuvonen, P. J.; Niemi, M. The Effect of SLCO1B1 Polymorphism on Repaglinide Pharmacokinetics Persists Over a Wide Dose Range. Br. J. Clin. Pharmacol. 2008, 66, 818-825.
84. Niemi, M.; Kivisto, K. T.; Hofmann, U.; Schwab, M.; Eichelbaum, M.; Fromm, M. F. Fexofenadine Pharmacokinetics Are Associated With a Polymorphism of the SLCO1B1 Gene (Encoding OATP1B1). Br. J. Clin. Pharmacol. 2005, 59, 602-604. (Pubitemid 40632253)
85. Kalliokoski, A.; Backman, J.; Kurkinen, K.; Neuvonen, P., Niemi M. Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism. Clin. Pharmacol. Ther. 2008, PMID: 18418370.
86. Pasanen, M. K.; Fredrikson, H.; Neuvonen, P. J.; Niemi, M. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin. Clin. Pharmacol. Ther. 2007, 82, 726-733. (Pubitemid 350114817)
87. Maeda, K.; Ieiri, I.; Yasuda, K.; Fujino, A.; Fujiwara, H.; Otsubo, K.; Hirano, M.; Watanabe, T.; Kitamura, Y.; Kusuhara, H.; Sugiyama, Y. Effects of Organic Anion Transporting Polypeptide 1B1 Haplotype on Pharmacokinetics of Pravastatin, Valsartan, and Temocapril. Clin. Pharmacol. Ther. 2006, 79, 427-439.
88. Zhang, W.; He, Y. J.; Han, C. T.; Liu, Z. Q.; Li, Q.; Fan, L.; Tan, Z. R.; Zhang, W. X.; Yu, B. N.; Wang, D.; Hu, D. L.; Zhou, H. H. Effect of SLCO1B1 Genetic Polymorphism on the Pharmacokinetics of Nateglinide. Br. J. Clin. Pharmacol. 2006, 62, 567-572. (Pubitemid 44571578)
89. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 Variants and Statin-Induced Myopathy - a Genomewide Study. N. Engl. J. Med. 2008, 359, 789-799.
90. Furihata, T.; Satoh, N.; Ohishi, T.; Ugajin, M.; Kameyama, Y.; Morimoto, K.; Matsumoto, S.; Yamashita, K.; Kobayashi, K.; Chiba, K. Functional Analysis of a Mutation in the SLCO1B1 Gene (c.1628T>G) Identified in a Japanese Patient With Pravastatin-Induced Myopathy. Pharmacogenomics J. 2009, 9, 185-193.
91. Morimoto, K.; Oishi, T.; Ueda, S.; Ueda, M.; Hosokawa, M.; Chiba, K. A Novel Variant Allele of OATP-C (SLCO1B1) Found in a Japanese Patient With Pravastatin-Induced Myopathy. Drug Metab. Pharmacokinet. 2004, 19, 453-455.
92. Zhang, W.; Chen, B. L.; Ozdemir, V.; He, Y. J.; Zhou, G.; Peng, D. D.; Deng, S.; Xie, Q. Y.; Xie, W.; Xu, L. Y.; Wang, L. C.; Fan, L.; Wang, A.; Zhou, H. H. SLCO1B1 521T - >C Functional Genetic Polymorphism and Lipid-Lowering Efficacy of Multiple-Dose Pravastatin in Chinese Coronary Heart Disease Patients. Br. J. Clin. Pharmacol. 2007, 64, 346-352.
93. Couvert, P.; Giral, P.; Dejager, S.; Gu, J.; Huby, T.; Chapman, M. J.; Bruckert, E.; Carrie, A. Association Between a Frequent Allele of the Gene Encoding OATP1B1 and Enhanced LDL-Lowering Response to Fluvastatin Therapy. Pharmacogenomics 2008, 9, 1217-1227.
94. Nozawa, T.; Minami, H.; Sugiura, S.; Tsuji, A.; Tamai, I. Role of Organic Anion Transporter OATP1B1 (OATP-C) in Hepatic Uptake of Irinotecan and Its Active Metabolite, 7-Ethyl-10-Hydroxycamptothecin: in Vitro Evidence and Effect of Single Nucleotide Polymorphisms. Drug Metab. Dispos. 2005, 33, 434-439. (Pubitemid 40279945)
95. Takane, H.; Kawamoto, K.; Sasaki, T.; Moriki, K.; Moriki, K.; Kitano, H.; Higuchi, S.; Otsubo, K.; Ieiri, I. Life-Threatening Toxicities in a Patient With UGT1A1*6/*28 and SLCO1B1*15/*15 Genotypes After Irinotecan-Based Chemotherapy. Cancer Chemother. Pharmacol. 2009, 63, 1165-1169.
96. Pasanen, M. K.; Miettinen, T. A.; Gylling, H.; Neuvonen, P. J.; Niemi, M. Polymorphism of the Hepatic Influx Transporter Organic Anion Transporting Polypeptide 1B1 Is Associated With Increased Cholesterol Synthesis Rate. Pharmacogenet. Genomics 2008, 18, 921-926.
97. Briz, O.; Serrano, M. A.; MacIas, R. I.; Gonzalez-Gallego, J.; Marin, J. J. Role of Organic Anion-Transporting Polypeptides, OATP-A, OATP-C and OATP-8, in the Human Placenta-Maternal Liver Tandem Excretory Pathway for Foetal Bilirubin. Biochem. J. 2003, 371, 897-905.
98. Hamada, A.; Sissung, T.; Price, D. K.; Danesi, R.; Chau, C. H.; Sharifi, N.; Venzon, D.; Maeda, K.; Nagao, K.; Sparreboom, A.; Mitsuya, H.; Dahut, W. L.; Figg, W. D. Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients With Androgen-Independent Prostatic Cancer. Clin. Cancer Res. 2008, 14, 3312-3318.
99. Ballestero, M. R.; Monte, M. J.; Briz, O.; Jimenez, F.; Gonzalez-San Martin, F.; Marin, J. J. Expression of Transporters Potentially Involved in the Targeting of Cytostatic Bile Acid Derivatives to Colon Cancer and Polyps. Biochem. Pharmacol. 2006, 72, 729-738.
100. Ismair, M. G.; Stieger, B.; Cattori, V.; Hagenbuch, B.; Fried, M.; Meier, P. J.; Kullak-Ublick, G. A. Hepatic Uptake of Cholecystokinin Octapeptide by Organic Anion-Transporting Polypeptides OATP4 and OATP8 of Rat and Human Liver. Gastroenterology 2001, 121, 1185-1190.
101. Kullak-Ublick, G. A.; Ismair, M. G.; Stieger, B.; Landmann, L.; Huber, R.; Pizzagalli, F.; Fattinger, K.; Meier, P. J.; Hagenbuch, B. Organic Anion-Transporting Polypeptide B (OATP-B) and Its Functional Comparison With Three Other OATPs of Human Liver. Gastroenterology 2001, 120, 525-533.
102. Letschert, K.; Keppler, D.; Konig, J. Mutations in the SLCO1B3 Gene Affecting the Substrate Specificity of the Hepatocellular Uptake Transporter OATP1B3 (OATP8). Pharmacogenetics 2004, 14, 441-452. (Pubitemid 38971234)
103. Ishiguro, N.; Maeda, K.; Kishimoto, W.; Saito, A.; Harada, A.; Ebner, T.; Roth, W.; Igarashi, T.; Sugiyama, Y. Predominant Contribution of OATP1B3 to the Hepatic Uptake of Telmisartan, an Angiotensin II Receptor Antagonist, in Humans. Drug Metab. Dispos. 2006, 34, 1109-1115. (Pubitemid 43920869)
104. Ishiguro, N.; Maeda, K.; Saito, A.; Kishimoto, W.; Matsushima, S.; Ebner, T.; Roth, W.; Igarashi, T.; Sugiyama, Y. Establishment of a Set of Double Transfectants Coexpressing Organic Anion Transporting Polypeptide 1B3 and Hepatic Efflux Transporters for the Characterization of the Hepatobiliary Transport of Telmisartan Acylglucuronide. Drug Metab. Dispos. 2008, 36, 796-805.
105. Miura, M.; Satoh, S.; Inoue, K.; Saito, M.; Habuchi, T.; Suzuki, T. Telmisartan Pharmacokinetics in Japanese Renal Transplant Recipients. Clin. Chim. Acta 2009, 399, 83-87.
106. Smith, N. F.; Acharya, M. R.; Desai, N.; Figg, W. D.; Sparreboom, A. Identification of OATP1B3 As a High-Affinity Hepatocellular Transporter of Paclitaxel. Cancer Biol. Ther. 2005, 4, 815-818.
107. Smith, N. F.; Marsh, S.; Scott-Horton, T. J.; Hamada, A.; Mielke, S.; Mross, K.; Figg, W. D.; Verweij, J.; McLeod, H. L.; Sparreboom, A. Variants in the SLCO1B3 Gene: Interethnic Distribution and Association With Paclitaxel Pharmacokinetics. Clin. Pharmacol. Ther. 2007, 81, 76-82. (Pubitemid 46050869)
108. Baker, S.; Verweij, J.; Cusatis, G.; van Schaik, R.; Marsh, S.; Orwick, S.; Franke, R.; Hu, S.; Schuetz, E.; Lamba, V.; Messersmith, W.; Wolff, A.; Carducci, M.; Sparreboom, A. Pharmacogenetic Pathway Analysis of Docetaxel Elimination. Clin. Pharmacol. Ther. 2009, 85, 155-163.
109. Franke, R. M.; Baker, S. D.; Mathijssen, R. H.; Schuetz, E. G.; Sparreboom, A. Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes. Clin. Pharmacol. Ther. 2008, 84, 704-709.
110. Sharifi, N.; Hamada, A.; Sissung, T.; Danesi, R.; Venzon, D.; Baum, C.; Gulley, J. L.; Price, D. K.; Dahut, W. L.; Figg, W. D. A Polymorphism in a Transporter of Testosterone Is a Determinant of Androgen Independence in Prostate Cancer. BJU Int. 2008, 102, 617-621.
111. Hagenbuch, B.; Gui, C. Xenobiotic Transporters of the Human Organic Anion Transporting Polypeptides (OATP) Family. Xenobiotica 2008, 38, 778-801.
112. Nozawa, T.; Nakajima, M.; Tamai, I.; Noda, K.; Nezu, J.; Sai, Y.; Tsuji, A.; Yokoi, T. Genetic Polymorphisms of Human Organic Anion Transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele Frequencies in the Japanese Population and Functional Analysis. J. Pharmacol. Exp. Ther. 2002, 302, 804-813. (Pubitemid 34787251)
113. Tamai, I.; Nozawa, T.; Koshida, M.; Nezu, J.; Sai, Y.; Tsuji, A. Functional Characterization of Human Organic Anion Transporting Polypeptide B (OATP-B) in Comparison With Liver-Specific OATP-C. Pharm. Res. 2001, 18, 1262-1269. (Pubitemid 32846318)
114. Grube, M.; Kock, K.; Oswald, S.; Draber, K.; Meissner, K.; Eckel, L.; Bohm, M.; Felix, S. B.; Vogelgesang, S.; Jedlitschky, G.; Siegmund, W.; Warzok, R.; Kroemer, H. K. Organic Anion Transporting Polypeptide 2B1 Is a High-Affinity Transporter for Atorvastatin and Is Expressed in the Human Heart. Clin. Pharmacol. Ther. 2006, 80, 607-620.
115. Grube, M.; Reuther, S.; Meyer Zu, S. H.; Kock, K.; Draber, K.; Ritter, C. A.; Fusch, C.; Jedlitschky, G.; Kroemer, H. K. Organic Anion Transporting Polypeptide 2B1 and Breast Cancer Resistance Protein Interact in the Transepithelial Transport of Steroid Sulfates in Human Placenta. Drug Metab. Dispos. 2007, 35, 30-35. (Pubitemid 46036473)
116. Niessen, J.; Jedlitschky, G.; Grube, M.; Bien, S.; Schwertz, H.; Ohtsuki, S.; Kawakami, H.; Kamiie, J.; Oswald, S.; Starke, K.; Strobel, U.; Siegmund, W.; Rosskopf, D.; Greinacher, A.; Terasaki, T.; Kroemer, H. K. Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin. Drug Metab. Dispos. 2009, 37, 1129-1137.
117. Tamai, I.; Nezu, J.; Uchino, H.; Sai, Y.; Oku, A.; Shimane, M.; Tsuji, A. Molecular Identification and Characterization of Novel Members of the Human Organic Anion Transporter (OATP) Family. Biochem. Biophys. Res. Commun. 2000, 273, 251-260.
118. Vaidyanathan, S.; Camenisch, G.; Schuetz, H.; Reynolds, C.; Yeh, C. M.; Bizot, M. N.; Dieterich, H. A.; Howard, D.; Dole, W. P. Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: the Role of P-Glycoprotein in the Disposition of Aliskiren. J. Clin. Pharmacol. 2008, 48, 1323-1338.
119. Seki, S.; Kobayashi, M.; Itagaki, S.; Hirano, T.; Iseki, K. Contribution of Organic Anion Transporting Polypeptide OATP2B1 to Amiodarone Accumulation in Lung Epithelial Cells. Biochim. Biophys. Acta 2009, 1788, 911-917.
120. Kitamura, S.; Maeda, K.; Wang, Y.; Sugiyama, Y. Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin. Drug Metab. Dispos. 2008, 36, 2014-2023.
121. Kobayashi, D.; Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in PH-Dependent Transport Across Intestinal Apical Membrane. J. Pharmacol. Exp. Ther. 2003, 306, 703-708. (Pubitemid 36886171)
122. Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Functional Characterization of PH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human. J. Pharmacol. Exp. Ther. 2004, 308, 438-445. (Pubitemid 38134202)
123. Satoh, H.; Yamashita, F.; Tsujimoto, M.; Murakami, H.; Koyabu, N.; Ohtani, H.; Sawada, Y. Citrus Juices Inhibit the Function of Human Organic Anion-Transporting Polypeptide OATP-B. Drug Metab. Dispos. 2005, 33, 518-523. (Pubitemid 40393194)
124. Mougey, E. B.; Feng, H.; Castro, M.; Irvin, C. G.; Lima, J. J. Absorption of Montelukast Is Transporter Mediated: a Common Variant of OATP2B1 Is Associated With Reduced Plasma Concentrations and Poor Response. Pharmacogenet. Genomics 2009, 19, 129-138.
125. Gui, C.; Miao, Y.; Thompson, L.; Wahlgren, B.; Mock, M.; Stieger, B.; Hagenbuch, B. Effect of Pregnane X Receptor Ligands on Transport Mediated by Human OATP1B1 and OATP1B3. Eur. J. Pharmacol. 2008, 584, 57-65.
126. Goodman & Gilman's The Pharmacological Basis of Therapeutics; McGraw-Hill Medical Publishing Division: 2008.
127. Tirona, R. G.; Leake, B. F.; Wolkoff, A. W.; Kim, R. B. Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation. J. Pharmacol. Exp. Ther. 2003, 304, 223-228.
128. Vavricka, S. R.; Van Montfoort, J.; Ha, H. R.; Meier, P. J.; Fattinger, K. Interactions of Rifamycin SV and Rifampicin With Organic Anion Uptake Systems of Human Liver. Hepatology 2002, 36, 164-172. (Pubitemid 34700774)
129. Zaher, H.; zu Schwabedissen, H. E.; Tirona, R. G.; Cox, M. L.; Obert, L. A.; Agrawal, N.; Palandra, J.; Stock, J. L.; Kim, R. B.; Ware, J. A. Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (Oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin. Mol. Pharmacol. 2008, 74, 320-329.
130. Niemi, M.; Kivisto, K. T.; Diczfalusy, U.; Bodin, K.; Bertilsson, L.; Fromm, M. F.; Eichelbaum, M. Effect of SLCO1B1 Polymorphism on Induction of CYP3A4 by Rifampicin. Pharmacogenet. Genomics 2006, 16, 565-568. (Pubitemid 44100201)
131. Zhang, W.; He, Y. J.; Gan, Z.; Fan, L.; Li, Q.; Wang, A.; Liu, Z. Q.; Deng, S.; Huang, Y. F.; Xu, L. Y.; Zhou, H. H. OATP1B1 Polymorphism Is a Major Determinant of Serum Bilirubin Level but Not Associated With Rifampicin-Mediated Bilirubin Elevation. Clin. Exp. Pharmacol. Physiol. 2007, 34, 1240-1244.
132. Kajosaari, L. I.; Niemi, M.; Neuvonen, M.; Laitila, J.; Neuvonen, P. J.; Backman, J. T. Cyclosporine Markedly Raises the Plasma Concentrations of Repaglinide. Clin. Pharmacol. Ther. 2005, 78, 388-399.
133. Lau, Y. Y.; Okochi, H.; Huang, Y.; Benet, L. Z. Pharmacokinetics of Atorvastatin and Its Hydroxy Metabolites in Rats and the Effects of Concomitant Rifampicin Single Doses: Relevance of First-Pass Effect From Hepatic Uptake Transporters, and Intestinal and Hepatic Metabolism. Drug Metab. Dispos. 2006, 34, 1175-1181.
134. Lau, Y. Y.; Huang, Y.; Frassetto, L.; Benet, L. Z. Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers. Clin. Pharmacol. Ther. 2007, 81, 194-204. (Pubitemid 46174816)
135. Backman, J. T.; Luurila, H.; Neuvonen, M.; Neuvonen, P. J. Rifampin Markedly Decreases and Gemfibrozil Increases the Plasma Concentrations of Atorvastatin and Its Metabolites. Clin. Pharmacol. Ther. 2005, 78, 154-167.
136. Simonson, S. G.; Raza, A.; Martin, P. D.; Mitchell, P. D.; Jarcho, J. A.; Brown, C. D.; Windass, A. S.; Schneck, D. W. Rosuvastatin Pharmacokinetics in Heart Transplant Recipients Administered an Antirejection Regimen Including Cyclosporine. Clin. Pharmacol. Ther. 2004, 76, 167-177.
137. Park, J. W.; Siekmeier, R.; Merz, M.; Krell, B.; Harder, S.; Marz, W.; Seidel, D.; Schuler, S.; Gross, W. Pharmacokinetics of Pravastatin in Heart-Transplant Patients Taking Cyclosporin A. Int. J. Clin. Pharmacol. Ther. 2002, 40, 439-450.
138. Jacobson, T. A. Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered With Cytochrome P450 Inhibitors. Am. J. Cardiol. 2004, 94, 1140-1146.
139. Seithel, A.; Eberl, S.; Singer, K.; Auge, D.; Heinkele, G.; Wolf, N. B.; Dorje, F.; Fromm, M. F.; Konig, J. The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 2007, 35, 779-786. (Pubitemid 46641549)
140. Kyrklund, C.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J. Gemfibrozil Increases Plasma Pravastatin Concentrations and Reduces Pravastatin Renal Clearance. Clin. Pharmacol. Ther. 2003, 73, 538-544.
141. Nakagomi-Hagihara, R.; Nakai, D.; Tokui, T.; Abe, T.; Ikeda, T. Gemfibrozil and Its Glucuronide Inhibit the Hepatic Uptake of Pravastatin Mediated by OATP1B1. Xenobiotica 2007, 37, 474-486.
142. Gustavson, L. E.; Schweitzer, S. M.; Koehne-Voss, S.; Achari, R.; Chira, T. O.; Esslinger, H. U.; Yannicelli, H. D. The Effects of Multiple Doses of Fenofibrate on the Pharmacokinetics of Pravastatin and Its 3alpha-Hydroxy Isomeric Metabolite. J. Clin. Pharmacol. 2005, 45, 947-953.
143. Oswald, S.; Giessmann, T.; Luetjohann, D.; Wegner, D.; Rosskopf, D.; Weitschies, W.; Siegmund, W. Disposition and Sterol-Lowering Effect of Ezetimibe Are Influenced by Single-Dose Coadministration of Rifampin, an Inhibitor of Multidrug Transport Proteins. Clin. Pharmacol. Ther. 2006, 80, 477-485.
144. Oswald, S.; Konig, J.; Lutjohann, D.; Giessmann, T.; Kroemer, H. K.; Rimmbach, C.; Rosskopf, D.; Fromm, M. F.; Siegmund, W. Disposition of Ezetimibe Is Influenced by Polymorphisms of the Hepatic Uptake Carrier OATP1B1. Pharmacogenet. Genomics 2008, 18, 559-568.
145. Oswald, S.; Haenisch, S.; Fricke, C.; Sudhop, T.; Remmler, C.; Giessmann, T.; Jedlitschky, G.; Adam, U.; Dazert, E.; Warzok, R.; Wacke, W.; Cascorbi, I.; Kroemer, H. K.; Weitschies, W.; von Bergmann, K.; Siegmund, W. Intestinal Expression of P-Glycoprotein (ABCB1), Multidrug Resistance Associated Protein 2 (ABCC2), and Uridine Diphosphate-Glucuronosyltransferase 1A1 Predicts the Disposition and Modulates the Effects of the Cholesterol Absorption Inhibitor Ezetimibe in Humans. Clin. Pharmacol. Ther. 2006, 79, 206-217. (Pubitemid 43297013)
146. Katz, D. A.; Carr, R.; Grimm, D. R.; Xiong, H.; Holley-Shanks, R.; Mueller, T.; Leake, B.; Wang, Q.; Han, L.; Wang, P. G.; Edeki, T.; Sahelijo, L.; Doan, T.; Allen, A.; Spear, B. B.; Kim, R. B. Organic Anion Transporting Polypeptide 1B1 Activity Classified by SLCO1B1 Genotype Influences Atrasentan Pharmacokinetics. Clin. Pharmacol. Ther. 2006, 79, 186-196.
147. Xiong, H.; Carr, R. A.; Locke, C. S.; Katz, D. A.; Achari, R.; Doan, T. T.; Wang, P.; Jankowski, J. R.; Sleep, D. J. Dual Effects of Rifampin on the Pharmacokinetics of Atrasentan. J. Clin. Pharmacol. 2007, 47, 423-429.
148. Gibbs, M. A.; Thummel, K. E.; Shen, D. D.; Kunze, K. L. Inhibition of Cytochrome P-450 3A (CYP3A) in Human Intestinal and Liver Microsomes: Comparison of Ki Values and Impact of CYP3A5 Expression. Drug Metab. Dispos. 1999, 27, 180-187.
149. van Giersbergen, P. L.; Treiber, A.; Schneiter, R.; Dietrich, H.; Dingemanse, J. Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects. Clin. Pharmacol. Ther. 2007, 81, 414-419. (Pubitemid 46364484)
150. Kajosaari, L. I.; Laitila, J.; Neuvonen, P. J.; Backman, J. T. Metabolism of Repaglinide by CYP2C8 and CYP3A4 in Vitro: Effect of Fibrates and Rifampicin. Basic Clin. Pharmacol. Toxicol. 2005, 97, 249-256.
151. Treiber, A.; Schneiter, R.; Hausler, S.; Stieger, B. Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake As the Common Mechanism of Its Interactions With Cyclosporin A, Rifampicin, and Sildenafil. Drug Metab. Dispos. 2007, 35, 1400-1407. (Pubitemid 47121782)
152. Treiber, A.; Schneiter, R.; Delahaye, S.; Clozel, M. Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction Between Bosentan and Cyclosporin A in the Rat. J. Pharmacol. Exp. Ther. 2004, 308, 1121-1129. (Pubitemid 38263989)
153. Niemi, M.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J.; Kivisto, K. T. Rifampin Decreases the Plasma Concentrations and Effects of Repaglinide. Clin. Pharmacol. Ther. 2000, 68, 495-500. (Pubitemid 30953869)
154. Bidstrup, T. B.; Stilling, N.; Damkier, P.; Scharling, B.; Thomsen, M. S.; Brosen, K. Rifampicin Seems to Act As Both an Inducer and an Inhibitor of the Metabolism of Repaglinide. Eur. J. Clin. Pharmacol. 2004, 60, 109-114. (Pubitemid 38626440)
155. Chen, Y.; Kissling, G.; Negishi, M.; Goldstein, J. A. The Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Cross-Talk With Hepatic Nuclear Factor 4alpha to Synergistically Activate the Human CYP2C9 Promoter. J. Pharmacol. Exp. Ther. 2005, 314, 1125-1133. (Pubitemid 41205977)
156. Ferguson, S. S.; LeCluyse, E. L.; Negishi, M.; Goldstein, J. A. Regulation of Human CYP2C9 by the Constitutive Androstane Receptor: Discovery of a New Distal Binding Site. Mol. Pharmacol. 2002, 62, 737-746.
157. Chen, Y.; Ferguson, S. S.; Negishi, M.; Goldstein, J. A. Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor. J. Pharmacol. Exp. Ther. 2004, 308, 495-501.
158. Chen, Y.; Ferguson, S. S.; Negishi, M.; Goldstein, J. A. Identification of Constitutive Androstane Receptor and Glucocorticoid Receptor Binding Sites in the CYP2C19 Promoter. Mol. Pharmacol. 2003, 64, 316-324.
159. Wang, H.; Faucette, S.; Sueyoshi, T.; Moore, R.; Ferguson, S.; Negishi, M.; LeCluyse, E. L. A Novel Distal Enhancer Module Regulated by Pregnane X Receptor/Constitutive Androstane Receptor Is Essential for the Maximal Induction of CYP2B6 Gene Expression. J. Biol. Chem. 2003, 278, 14146-14152.
160. Wang, H.; Faucette, S.; Moore, R.; Sueyoshi, T.; Negishi, M.; LeCluyse, E. Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin. J. Biol. Chem. 2004, 279, 29295-29301. (Pubitemid 38915806)
161. Goodwin, B.; Moore, L. B.; Stoltz, C. M.; McKee, D. D.; Kliewer, S. A. Regulation of the Human CYP2B6 Gene by the Nuclear Pregnane X Receptor. Mol. Pharmacol. 2001, 60, 427-431. (Pubitemid 32781548)
162. Sugatani, J.; Nishitani, S.; Yamakawa, K.; Yoshinari, K.; Sueyoshi, T.; Negishi, M.; Miwa, M. Transcriptional Regulation of Human UGT1A1 Gene Expression: Activated Glucocorticoid Receptor Enhances Constitutive Androstane Receptor/Pregnane X Receptor-Mediated UDP-Glucuronosyltransferase 1A1 Regulation With Glucocorticoid Receptor-Interacting Protein 1. Mol. Pharmacol. 2005, 67, 845-855. (Pubitemid 40365332)
163. Sugatani, J.; Mizushima, K.; Osabe, M.; Yamakawa, K.; Kakizaki, S.; Takagi, H.; Mori, M.; Ikari, A.; Miwa, M. Transcriptional Regulation of Human UGT1A1 Gene Expression Through Distal and Proximal Promoter Motifs: Implication of Defects in the UGT1A1 Gene Promoter. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 377, 597-605.
164. Gardner-Stephen, D.; Heydel, J. M.; Goyal, A.; Lu, Y.; Xie, W.; Lindblom, T.; Mackenzie, P.; Radominska-Pandya, A. Human PXR Variants and Their Differential Effects on the Regulation of Human UDP-Glucuronosyltransferase Gene Expression. Drug Metab. Dispos. 2004, 32, 340-347.
165. Echchgadda, I.; Song, C. S.; Oh, T.; Ahmed, M.; De, L. C.; IChatterjee, B. The Xenobiotic-Sensing Nuclear Receptors Pregnane X Receptor, Constitutive Androstane Receptor, and Orphan Nuclear Receptor Hepatocyte Nuclear Factor 4alpha in the Regulation of Human Steroid-/Bile Acid-Sulfotransferase. Mol. Endocrinol. 2007, 21, 2099-2111.
166. Arnold, K. A.; Eichelbaum, M.; Burk, O. Alternative Splicing Affects the Function and Tissue-Specific Expression of the Human Constitutive Androstane Receptor. Nucl. Recept. 2004, 2, 1. (Pubitemid 39130379)
167. Burk, O.; Arnold, K. A.; Nussler, A. K.; Schaeffeler, E.; Efimova, E.; Avery, B. A.; Avery, M. A.; Fromm, M. F.; Eichelbaum, M. Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1 Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane Receptor. Mol. Pharmacol. 2005, 67, 1954-1965. (Pubitemid 41007777)
168. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin. J. Biol. Chem. 2001, 276, 14581-14587. (Pubitemid 37373327)
169. Assem, M.; Schuetz, E. G.; Leggas, M.; Sun, D.; Yasuda, K.; Reid, G.; Zelcer, N.; Adachi, M.; Strom, S.; Evans, R. M.; Moore, D. D.; Borst, P.; Schuetz, J. D. Interactions Between Hepatic Mrp4 and Sult2a As Revealed by the Constitutive Androstane Receptor and Mrp4 Knockout Mice. J. Biol. Chem. 2004, 279, 22250-22257.
170. Meyer zu Schwabedissen, H. E.; Tirona, R. G.; Yip, C. S.; Ho, R. H.; Kim, R. B. Interplay Between the Nuclear Receptor Pregnane X Receptor and the Uptake Transporter Organic Anion Transporter Polypeptide 1A2 Selectively Enhances Estrogen Effects in Breast Cancer. Cancer Res. 2008, 68, 9338-9347.
171. Miki, Y.; Suzuki, T.; Kitada, K.; Yabuki, N.; Shibuya, R.; Moriya, T.; Ishida, T.; Ohuchi, N.; Blumberg, B.; Sasano, H. Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma. Cancer Res. 2006, 66, 535-542. (Pubitemid 43168338)
172. Cui, Y.; Konig, J.; Leier, I.; Buchholz, U.; Keppler, D. Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6. J. Biol. Chem. 2001, 276, 9626-9630. (Pubitemid 37391856)
173. Briz, O.; Romero, M. R.; Martinez-Becerra, P.; MacIas, R. I.; Perez, M. J.; Jimenez, F.; San Martin, F. G.; Marin, J. J. OATP8/1B3-Mediated Cotransport of Bile Acids and Glutathione: an Export Pathway for Organic Anions From Hepatocytes? J. Biol. Chem. 2006, 281, 30326-30335. (Pubitemid 44582086)
174. Maeda, K.; Kambara, M.; Tian, Y.; Hofmann, A. F.; Sugiyama, Y. Uptake of Ursodeoxycholate and Its Conjugates by Human Hepatocytes: Role of Na(+)-Taurocholate Cotransporting Polypeptide (NTCP), Organic Anion Transporting Polypeptide (OATP) 1B1 (OATP-C), and Oatp1B3 (OATP8). Mol. Pharmaceutics 2006, 3, 70-77. (Pubitemid 43331753)
175. Yamaguchi, H.; Kobayashi, M.; Okada, M.; Takeuchi, T.; Unno, M.; Abe, T.; Goto, J.; Hishinuma, T.; Mano, N. Rapid Screening of Antineoplastic Candidates for the Human Organic Anion Transporter OATP1B3 Substrates Using Fluorescent Probes. Cancer Lett. 2008, 260, 163-169.
176. Yamaguchi, H.; Okada, M.; Akitaya, S.; Ohara, H.; Mikkaichi, T.; Ishikawa, H.; Sato, M.; Matsuura, M.; Saga, T.; Unno, M.; Abe, T.; Mano, N.; Hishinuma, T.; Goto, J. Transport of Fluorescent Chenodeoxycholic Acid Via the Human Organic Anion Transporters OATP1B1 and OATP1B3. J. Lipid Res. 2006, 47, 1196-1202. (Pubitemid 43830711)
177. Nakai, D.; Nakagomi, R.; Furuta, Y.; Tokui, T.; Abe, T.; Ikeda, T.; Nishimura, K. Human Liver-Specific Organic Anion Transporter, LST-1, Mediates Uptake of Pravastatin by Human Hepatocytes. J. Pharmacol. Exp. Ther. 2001, 297, 861-867.
178. Konig, J.; Cui, Y.; Nies, A. T.; Keppler, D. Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide. J. Biol. Chem. 2000, 275, 23161-23168. (Pubitemid 30646210)
179. Hirano, M.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans. J. Pharmacol. Exp. Ther. 2004, 311, 139-146. (Pubitemid 39287793)
180. Takada, T.; Weiss, H. M.; Kretz, O.; Gross, G.; Sugiyama, Y. Hepatic Transport of PKI166, an Epidermal Growth Factor Receptor Kinase Inhibitor of the Pyrrolo-Pyrimidine Class, and Its Main Metabolite, ACU154. Drug Metab. Dispos. 2004, 32, 1272-1278. (Pubitemid 39410912)
181. Letschert, K.; Faulstich, H.; Keller, D.; Keppler, D. Molecular Characterization and Inhibition of Amanitin Uptake into Human Hepatocytes. Toxicol. Sci. 2006, 91, 140-149.
182. Lu, W. J.; Tamai, I.; Nezu, J.; Lai, M. L.; Huang, J. D. Organic Anion Transporting Polypeptide-C Mediates Arsenic Uptake in HEK-293Cells. J. Biomed. Sci. 2006, 13, 525-533.
183. Lau, Y. Y.; Okochi, H.; Huang, Y.; Benet, L. Z. Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and Ex Situ Systems. J. Pharmacol. Exp. Ther. 2006, 316, 762-771. (Pubitemid 43131004)
184. Briz, O.; Serrano, M. A.; Rebollo, N.; Hagenbuch, B.; Meier, P. J.; Koepsell, H.; Marin, J. J. Carriers Involved in Targeting the Cytostatic Bile Acid-Cisplatin Derivatives Cis-Diammine-Chloro-Cholylglycinate-Platinum(II) and Cis-Diammine-Bisursodeoxycholate-Platinum(II) Toward Liver Cells. Mol. Pharmacol. 2002, 61, 853-860.
185. Sandhu, P.; Lee, W.; Xu, X.; Leake, B. F.; Yamazaki, M.; Stone, J. A.; Lin, J. H.; Pearson, P. G.; Kim, R. B. Hepatic Uptake of the Novel Antifungal Agent Caspofungin. Drug Metab. Dispos. 2005, 33, 676-682.
186. Shitara, Y.; Hirano, M.; Sato, H.; Sugiyama, Y. Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction Between Cerivastatin and Gemfibrozil. J. Pharmacol. Exp. Ther. 2004, 311, 228-236.
187. Meier-Abt, F.; Faulstich, H.; Hagenbuch, B. Identification of Phalloidin Uptake Systems of Rat and Human Liver. Biochim. Biophys. Acta 2004, 1664, 64-69. (Pubitemid 38829318)
188. Liu, L.; Cui, Y.; Chung, A. Y.; Shitara, Y.; Sugiyama, Y.; Keppler, D.; Pang, K. S. Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers. J. Pharmacol. Exp. Ther. 2006, 318, 395-402.
189. Shimizu, M.; Fuse, K.; Okudaira, K.; Nishigaki, R.; Maeda, K.; Kusuhara, H.; Sugiyama, Y. Contribution of OATP (Organic Anion-Transporting Polypeptide) Family Transporters to the Hepatic Uptake of Fexofenadine in Humans. Drug Metab. Dispos. 2005, 33, 1477-1481. (Pubitemid 41323995)
190. Baldes, C.; Koenig, P.; Neumann, D.; Lenhof, H. P.; Kohlbacher, O.; Lehr, C. M. Development of a Fluorescence-Based Assay for Screening of Modulators of Human Organic Anion Transporter 1B3 (OATP1B3). Eur. J. Pharm. Biopharm. 2006, 62, 39-43.
191. Fischer, W. J.; Altheimer, S.; Cattori, V.; Meier, P. J.; Dietrich, D. R.; Hagenbuch, B. Organic Anion Transporting Polypeptides Expressed in Liver and Brain Mediate Uptake of Microcystin. Toxicol. Appl. Pharmacol. 2005, 203, 257-263. (Pubitemid 40311872)
192. Komatsu, M.; Furukawa, T.; Ikeda, R.; Takumi, S.; Nong, Q.; Aoyama, K.; Akiyama, S.; Keppler, D.; Takeuchi, T. Involvement of Mitogen-Activated Protein Kinase Signaling Pathways in Microcystin-LR-Induced Apoptosis After Its Selective Uptake Mediated by OATP1B1 and OATP1B3. Toxicol. Sci. 2007, 97, 407-416. (Pubitemid 47073856)
193. Nakagomi-Hagihara, R.; Nakai, D.; Kawai, K.; Yoshigae, Y.; Tokui, T.; Abe, T.; Ikeda, T. OATP1B1, OATP1B3, and Mrp2 Are Involved in Hepatobiliary Transport of Olmesartan, a Novel Angiotensin II Blocker. Drug Metab. Dispos. 2006, 34, 862-869.
194. Yamada, A.; Maeda, K.; Kamiyama, E.; Sugiyama, D.; Kondo, T.; Shiroyanagi, Y.; Nakazawa, H.; Okano, T.; Adachi, M.; Schuetz, J. D.; Adachi, Y.; Hu, Z.; Kusuhara, H.; Sugiyama, Y. Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor. Drug Metab. Dispos. 2007, 35, 2166-2176. (Pubitemid 350146202)
195. Fehrenbach, T.; Cui, Y.; Faulstich, H.; Keppler, D. Characterization of the Transport of the Bicyclic Peptide Phalloidin by Human Hepatic Transport Proteins. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 368, 415-420. (Pubitemid 37491501)
196. Fujino, H.; Nakai, D.; Nakagomi, R.; Saito, M.; Tokui, T.; Kojima, J. Metabolic Stability and Uptake by Human Hepatocytes of Pitavastatin, a New Inhibitor of HMG-CoA Reductase. Arzneimittelforschung 2004, 54, 382-388.
197. Sasaki, M.; Suzuki, H.; Ito, K.; Abe, T.; Sugiyama, Y. Transcellular Transport of Organic Anions Across a Double-Transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-Transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2). J. Biol. Chem. 2002, 277, 6497-6503. (Pubitemid 34968447)
198. Schneck, D. W.; Birmingham, B. K.; Zalikowski, J. A.; Mitchell, P. D.; Wang, Y.; Martin, P. D.; Lasseter, K. C.; Brown, C. D.; Windass, A. S.; Raza, A. The Effect of Gemfibrozil on the Pharmacokinetics of Rosuvastatin. Clin. Pharmacol. Ther. 2004, 75, 455-463.
199. Sakamoto, S.; Kusuhara, H.; Horie, K.; Takahashi, K.; Baba, T.; Ishizaki, J.; Sugiyama, Y. Identification of the Transporters Involved in the Hepatobiliary Transport and Intestinal Efflux of Methyl 1-(3,4-Dimethoxyphenyl)- 3-(3-Ethylvaleryl)-4-Hydroxy-6,7,8-Trimethoxy-2-Naphthoate (S-8921) Glucuronide, a Pharmacologically Active Metabolite of S-8921. Drug Metab. Dispos. 2008, 36, 1553-1561.
200. Sakamoto, K.; Mikami, H.; Kimura, J. Involvement of Organic Anion Transporting Polypeptides in the Toxicity of Hydrophilic Pravastatin and Lipophilic Fluvastatin in Rat Skeletal Myofibres. Br. J. Pharmacol. 2008, 154, 1482-1490.
201. Tsuda-Tsukimoto, M.; Maeda, T.; Iwanaga, T.; Kume, T.; Tamai, I. Characterization of Hepatobiliary Transport Systems of a Novel Alpha4beta1/Alpha4beta7 Dual Antagonist, TR-14035. Pharm. Res. 2006, 23, 2646-2656. (Pubitemid 44691611)
202. Nozawa, T.; Sugiura, S.; Nakajima, M.; Goto, A.; Yokoi, T.; Nezu, J.; Tsuji, A.; Tamai, I. Involvement of Organic Anion Transporting Polypeptides in the Transport of Troglitazone Sulfate: Implications for Understanding Troglitazone Hepatotoxicity. Drug Metab. Dispos. 2004, 32, 291-294. (Pubitemid 38263886)
203. Yamashiro, W.; Maeda, K.; Hirouchi, M.; Adachi, Y.; Hu, Z.; Sugiyama, Y. Involvement of Transporters in the Hepatic Uptake and Biliary Excretion of Valsartan, a Selective Antagonist of the Angiotensin II AT1-Receptor, in Humans. Drug Metab. Dispos. 2006, 34, 1247-1254. (Pubitemid 43920885)